Inverness Acquisition Of Unipath Could Lead To New Cardiology Diagnostics
This article was originally published in The Tan Sheet
Executive Summary
Inverness Medical Innovations' acquisition of home pregnancy test manufacturer Unipath and its immunodiagnostic technologies could lead to new self-diagnostic tools in the cardiology arena
You may also be interested in...
Inverness cements IVC acquisition
Device firm completes purchase of supplement marketer IVC Industries March 19; transaction will provide Inverness with "additional production and distribution resources," as well as private label presence, firm says (1"The Tan Sheet" Dec. 24, 2001, p. 7). Original agreement, announced Sept. 21, was amended in January to allow IVC stockholders to receive $2.50 in cash for each share of stock rather than exchange for shares of Inverness stock. For fourth quarter ending Dec. 31, Inverness recorded $13.7 mil. in sales, up 11.2% from last year; FY 2001 sales dipped 3.3% to $49.4 mil., firm says. Net losses were $25.9 mil and $24.7 mil. for Q4 and the year, respectively, attributable to Unipath acquisition, split-off/merger with J&J...
Inverness cements IVC acquisition
Device firm completes purchase of supplement marketer IVC Industries March 19; transaction will provide Inverness with "additional production and distribution resources," as well as private label presence, firm says (1"The Tan Sheet" Dec. 24, 2001, p. 7). Original agreement, announced Sept. 21, was amended in January to allow IVC stockholders to receive $2.50 in cash for each share of stock rather than exchange for shares of Inverness stock. For fourth quarter ending Dec. 31, Inverness recorded $13.7 mil. in sales, up 11.2% from last year; FY 2001 sales dipped 3.3% to $49.4 mil., firm says. Net losses were $25.9 mil and $24.7 mil. for Q4 and the year, respectively, attributable to Unipath acquisition, split-off/merger with J&J...
Inverness cements IVC acquisition
Device firm completes purchase of supplement marketer IVC Industries March 19; transaction will provide Inverness with "additional production and distribution resources," as well as private label presence, firm says (1"The Tan Sheet" Dec. 24, 2001, p. 7). Original agreement, announced Sept. 21, was amended in January to allow IVC stockholders to receive $2.50 in cash for each share of stock rather than exchange for shares of Inverness stock. For fourth quarter ending Dec. 31, Inverness recorded $13.7 mil. in sales, up 11.2% from last year; FY 2001 sales dipped 3.3% to $49.4 mil., firm says. Net losses were $25.9 mil and $24.7 mil. for Q4 and the year, respectively, attributable to Unipath acquisition, split-off/merger with J&J...